Bor‐Sheng Ko

6.9k total citations
141 papers, 3.8k citations indexed

About

Bor‐Sheng Ko is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Bor‐Sheng Ko has authored 141 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 55 papers in Molecular Biology and 31 papers in Genetics. Recurrent topics in Bor‐Sheng Ko's work include Acute Myeloid Leukemia Research (39 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers) and Lymphoma Diagnosis and Treatment (18 papers). Bor‐Sheng Ko is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers) and Lymphoma Diagnosis and Treatment (18 papers). Bor‐Sheng Ko collaborates with scholars based in Taiwan, United States and Singapore. Bor‐Sheng Ko's co-authors include Ming Yao, Yee‐Chun Chen, Hwei‐Fang Tien, Jih‐Luh Tang, Jun‐Yang Liou, Szu-Chun Hsu, Hsin‐An Hou, Wen‐Chien Chou, Shang‐Yi Huang and Woei Tsay and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Bor‐Sheng Ko

133 papers receiving 3.7k citations

Peers

Countries citing papers authored by Bor‐Sheng Ko

Since Specialization

Citations

This map shows the geographic impact of Bor‐Sheng Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bor‐Sheng Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bor‐Sheng Ko more than expected).

Fields of papers citing papers by Bor‐Sheng Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bor‐Sheng Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bor‐Sheng Ko. The network helps show where Bor‐Sheng Ko may publish in the future.

Co-authorship network of co-authors of Bor‐Sheng Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Bor‐Sheng Ko. A scholar is included among the top collaborators of Bor‐Sheng Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bor‐Sheng Ko. Bor‐Sheng Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations 2024 ·Blood Cancer Journal ·Feng‐Ming Tien, Chi‐Yuan Yao, Cheng‐Hong Tsai, (unknown), Chien‐Yuan Chen, (unknown), Chien‐Chin Lin, Yuan‐Yeh Kuo, Yen‐Ling Peng, Mei‐Hsuan Tseng, Yu-Sin Wu, Ming-Chih Liu, Liang‐In Lin, (unknown), Bor‐Sheng Ko, Ming Yao, Jih‐Luh Tang, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien	8
2	Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms 2024 ·Blood Cancer Journal ·(unknown), Chien‐Chin Lin, Cheng‐Hong Tsai, Feng‐Ming Tien, (unknown), Mei‐Hsuan Tseng, Yuan‐Yeh Kuo, (unknown), Ming-Chih Liu, Chang‐Tsu Yuan, (unknown), (unknown), Bor‐Sheng Ko, Jih‐Luh Tang, (unknown), (unknown), Hwei‐Fang Tien, Hsin‐An Hou, Wen‐Chien Chou	7
3	Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan 2023 ·Cancer Medicine ·(unknown), (unknown), Ming Yao, Liang‐Tsai Hsiao, Bor‐Sheng Ko, Chia‐Jen Liu, Tsai‐Yun Chen	1
4	Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML 2023 ·Blood Cancer Journal ·Cheng‐Hong Tsai, (unknown), (unknown), Feng‐Ming Tien, Yuan‐Yeh Kuo, Mei‐Hsuan Tseng, Yen‐Ling Peng, (unknown), Bor‐Sheng Ko, Jih‐Luh Tang, (unknown), Ming-Chih Liu, Chia‐Wen Liu, Chien‐Chin Lin, Ming Yao, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien	17
5	Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia 2023 ·American Journal of Hematology ·(unknown), Cheng‐Hong Tsai, Chien‐Chin Lin, Feng‐Ming Tien, Yuan‐Yeh Kuo, (unknown), Yen‐Ling Peng, (unknown), Mei‐Hsuan Tseng, (unknown), (unknown), Liang‐In Lin, (unknown), (unknown), Bor‐Sheng Ko, Jih‐Luh Tang, Ming Yao, Wen‐Chien Chou, Hsin‐An Hou, Hwei‐Fang Tien	19
6	Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry 2022 ·Cancers ·Cheng‐Hong Tsai, Tzu‐Ting Chen, Jyh‐Pyng Gau, Po‐Nan Wang, Yi‐Chang Liu, (unknown), Chi‐Cheng Li, Ming Yao, Bor‐Sheng Ko	7
7	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients 2021 ·Journal of the Formosan Medical Association ·Shang‐Yi Huang, Hsiu‐Hsia Lin, Ming Yao, Jih‐Luh Tang, Shang‐Ju Wu, Wen‐Chien Chou, Szu-Chun Hsu, Bor‐Sheng Ko, Hwei‐Fang Tien	1
8	Reduced Expression of Metallothionein-I/II in Renal Proximal Tubules Is Associated with Advanced Chronic Kidney Disease 2021 ·Toxins ·Yi-Jhu Lu, (unknown), (unknown), Bor‐Sheng Ko, Tzu-Ching Chang, Yi‐Ju Wu, Shu-Man Liang, Yee‐Jee Jan, Jun‐Yang Liou	6
9	A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data 2021 ·American Journal of Clinical Pathology ·Sara A. Monaghan, (unknown), Yen‐Chun Liu, (unknown), Michael Boyiadzis, Ting‐Yu Chang, Yu‐Fen Wang, Chi-Chun Lee, Steven H. Swerdlow, Bor‐Sheng Ko	26
10	Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017 2020 ·BMJ Open ·Shao‐Yi Huang, Ho‐Min Chen, (unknown), Bor‐Sheng Ko, Fei‐Yuan Hsiao	27
11	ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma 2019 ·Cell Death and Disease ·Yi‐Ju Wu, Bor‐Sheng Ko, Shu-Man Liang, Yi-Jhu Lu, Yee‐Jee Jan, Shih Sheng Jiang, Song‐Kun Shyue, Linyi Chen, Jun‐Yang Liou	22
12	Cordycepin Suppresses Endothelial Cell Proliferation, Migration, Angiogenesis, and Tumor Growth by Regulating Focal Adhesion Kinase and p53 2019 ·Cancers ·(unknown), Shu-Man Liang, (unknown), Yi‐Ju Wu, Yi-Jhu Lu, Yee‐Jee Jan, Bor‐Sheng Ko, Yung‐Jen Chuang, Song‐Kun Shyue, Cheng-Chin Kuo, Jun‐Yang Liou	24
13	Busulfan-Containing Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Lymphoblastic Leukemia: Single Tertiary Center Experience in Taiwan 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), Bor‐Sheng Ko, (unknown), Ming Yao, Jih‐Luh Tang	1
14	Women with Diffuse Large B Cell Lymphoma Benefit More from Rituximab-Containing Chemotherapy 2018 ·Journal of Women s Health ·Huai‐Hsuan Huang, Fei‐Yuan Hsiao, Li‐Ju Chen, Ho‐Min Chen, Bor‐Sheng Ko	5
15	Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan 2018 ·Hematology ·Bor‐Sheng Ko, Ming-Chih Chang, Tzeon-Jye Chiou, (unknown), (unknown), Sheng-Fung Lin, Cheng-Shyong Chang, (unknown), Su-Peng Yeh, Tsai‐Yun Chen, Wei-Shou Hwang	5
16	An Artificial Intelligence Approach for Predicting Allogeneic Hematopoietic Stem Cell Transplantation Outcome By Detecting Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry Data 2017 ·Blood ·Chi‐Cheng Li, Bor‐Sheng Ko, Yu‐Fen Wang, (unknown), (unknown), Hsin‐An Hou, (unknown), Chien‐Ting Lin, (unknown), (unknown), Hwei‐Fang Tien, Chi-Chun Lee, Jih‐Luh Tang	1
17	An Artificial Intelligence Approach for B Lymphoblastic Leukemia Minimal Residual Disease Detection and Clinical Prognosis Prediction Using Flow Cytometry Data 2017 ·Blood ·Yu‐Fen Wang, Bor‐Sheng Ko, Chi‐Cheng Li, (unknown), (unknown), Huai‐Hsuan Huang, Hsin‐An Hou, Hwei‐Fang Tien, Chi-Chun Lee, Jih‐Luh Tang	1
18	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study 2015 ·PLoS ONE ·Shang‐Yi Huang, Hsiu‐Hsia Lin, Ming Yao, Jih‐Luh Tang, Shang‐Ju Wu, Hsin‐An Hou, Wen‐Chien Chou, Sheng‐Chieh Chou, Szu-Chun Hsu, Bor‐Sheng Ko, (unknown), Woei Tsay, Hwei‐Fang Tien	15
19	Correction: Rho Kinases Regulate the Renewal and Neural Differentiation of Embryonic Stem Cells in a Cell Plating Density–Dependent Manner 2010 ·PLoS ONE ·Tzu‐Ching Chang, Yen‐Chung Chen, Minghua Yang, Chien‐Hung Chen, (unknown), Bor‐Sheng Ko, Jun‐Yang Liou, Kenneth K. Wu	8
20	The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles 2009 ·Biomaterials ·Dongming Huang, Jong‐Kai Hsiao, Ying‐Chun Chen, (unknown), Li‐Ying Chien, Ming Yao, Yin‐Kai Chen, Bor‐Sheng Ko, Szu-Chun Hsu, Lin‐Ai Tai, Huiying Cheng, Shih‐Wei Wang, Chung‐Shi Yang, Yee‐Chun Chen	290

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact